CR20210163A - Inhibidores de pde4 que contienen boro - Google Patents
Inhibidores de pde4 que contienen boroInfo
- Publication number
- CR20210163A CR20210163A CR20210163A CR20210163A CR20210163A CR 20210163 A CR20210163 A CR 20210163A CR 20210163 A CR20210163 A CR 20210163A CR 20210163 A CR20210163 A CR 20210163A CR 20210163 A CR20210163 A CR 20210163A
- Authority
- CR
- Costa Rica
- Prior art keywords
- containing boron
- pde4 inhibitors
- inhibitors containing
- pde4
- formula
- Prior art date
Links
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 title abstract 2
- 229910052796 boron Inorganic materials 0.000 title abstract 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 3
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 3
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invencion se refiere a compuestos que contienen boro de la Formula (I)X-Y-Z Formula (I) que inhiben la fosfodiesterasa 4 (PDE4). La invencion tambien comprende composiciones farmaceuticas que contienen estos compuestos y metodos para tratar enfermedades, afecciones o trastornos que mejoran mediante la inhibicion de PDE4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862741868P | 2018-10-05 | 2018-10-05 | |
| US201962889599P | 2019-08-21 | 2019-08-21 | |
| PCT/IB2019/058355 WO2020070651A1 (en) | 2018-10-05 | 2019-10-01 | Boron containing pde4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210163A true CR20210163A (es) | 2021-06-24 |
Family
ID=68136492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210163A CR20210163A (es) | 2018-10-05 | 2019-10-01 | Inhibidores de pde4 que contienen boro |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10946031B2 (es) |
| EP (1) | EP3861001B1 (es) |
| JP (1) | JP7048823B2 (es) |
| KR (1) | KR102576125B1 (es) |
| CN (1) | CN113166177B (es) |
| AU (1) | AU2019351960B2 (es) |
| BR (1) | BR112021005870B1 (es) |
| CA (1) | CA3114702C (es) |
| CL (1) | CL2021000843A1 (es) |
| CO (1) | CO2021003928A2 (es) |
| CR (1) | CR20210163A (es) |
| CU (1) | CU20210023A7 (es) |
| DK (1) | DK3861001T3 (es) |
| DO (1) | DOP2021000055A (es) |
| EC (1) | ECSP21023404A (es) |
| ES (1) | ES2974208T3 (es) |
| FI (1) | FI3861001T3 (es) |
| GE (2) | GEAP202215599A (es) |
| IL (1) | IL282083B2 (es) |
| MA (1) | MA53808A (es) |
| MX (1) | MX2021003871A (es) |
| NI (1) | NI202100020A (es) |
| PE (1) | PE20211546A1 (es) |
| PH (1) | PH12021550743A1 (es) |
| PY (1) | PY1983118A (es) |
| SG (1) | SG11202102674RA (es) |
| TW (1) | TWI764052B (es) |
| UY (1) | UY38400A (es) |
| WO (1) | WO2020070651A1 (es) |
| ZA (1) | ZA202101822B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021000795A (es) | 2018-07-24 | 2021-04-12 | Taiho Pharmaceutical Co Ltd | Compuestos heterociclicos para inhibir la actividad de shp2. |
| GB201911928D0 (en) | 2019-08-20 | 2019-10-02 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
| JP2023538362A (ja) * | 2020-08-20 | 2023-09-07 | ファイザー・インク | １（ｒ）－４－（５－（４－メトキシ－３－プロポキシフェニル）ピリジン－３－イル）－１，２－オキサボロラン－２－オールの安定な局所製剤 |
| EP4204012A1 (en) | 2020-08-31 | 2023-07-05 | Pfizer Inc. | Methods of protecting rna |
| JP7838832B2 (ja) * | 2020-12-25 | 2026-04-01 | 瑞石生物医薬有限公司 | ボレート誘導体及びその使用 |
| CN119403811A (zh) * | 2022-06-24 | 2025-02-07 | 瑞石生物医药有限公司 | 一种硼酸酯衍生物的可药用盐、其结晶形式及用途 |
| TW202404610A (zh) | 2022-06-24 | 2024-02-01 | 大陸商瑞石生物醫藥有限公司 | 一種硼酸酯衍生物的結晶、其製備方法及用途 |
| GB202306663D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Combination therapy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9411587D0 (en) | 1994-06-09 | 1994-08-03 | Zeneca Ltd | Compound, composition and use |
| ES2287971T3 (es) | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
| EP2343304B1 (en) * | 2005-02-16 | 2015-06-10 | Anacor Pharmaceuticals, Inc. | Biocidal boronophthalide compounds |
| JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| WO2009111676A2 (en) | 2008-03-06 | 2009-09-11 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules as anti-inflammatory agents |
| JP5745279B2 (ja) * | 2008-01-09 | 2015-07-08 | アナコール ファーマシューティカルズ，インコーポレイテッド | 抗炎症剤としてのホウ素含有小分子 |
| KR20150065941A (ko) * | 2008-03-06 | 2015-06-15 | 아나코르 파마슈티칼스 인코포레이티드 | 소염제로써 붕소가 함유된 소분자 |
| AU2011329485A1 (en) * | 2010-11-18 | 2013-04-18 | Glaxo Group Limited | Compounds |
| CN108142434A (zh) | 2011-10-07 | 2018-06-12 | 先正达参股股份有限公司 | 用于保护有用植物或植物繁殖材料的方法 |
| HRP20230162T1 (hr) * | 2012-10-25 | 2023-04-14 | Tetra Discovery Partners Llc | Heteroarilni inhibitori enzima pde4 |
| EP2752196A1 (en) * | 2013-01-03 | 2014-07-09 | Université Bordeaux Segalen | Selective nox-1 inhibitor peptides and uses thereof |
| MA38319A1 (fr) | 2013-01-30 | 2016-08-31 | Dow Agrosciences Llc | Utilisation des benzoxaboroles à titre d'agents antimicrobiens volatils sur les viandes, les plantes, ou des parties de plantes |
| WO2014147009A1 (en) * | 2013-03-18 | 2014-09-25 | Syngenta Participations Ag | Novel microbiocides |
| AU2014202928B1 (en) | 2013-06-05 | 2014-09-11 | Agrofresh Inc. | Compounds and compositions |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| US11919902B2 (en) * | 2017-12-22 | 2024-03-05 | Hibercell, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
-
2019
- 2019-10-01 CR CR20210163A patent/CR20210163A/es unknown
- 2019-10-01 MX MX2021003871A patent/MX2021003871A/es unknown
- 2019-10-01 EP EP19782756.1A patent/EP3861001B1/en active Active
- 2019-10-01 GE GEAP202215599A patent/GEAP202215599A/en unknown
- 2019-10-01 FI FIEP19782756.1T patent/FI3861001T3/fi active
- 2019-10-01 KR KR1020217013141A patent/KR102576125B1/ko active Active
- 2019-10-01 BR BR112021005870-2A patent/BR112021005870B1/pt active IP Right Grant
- 2019-10-01 AU AU2019351960A patent/AU2019351960B2/en not_active Ceased
- 2019-10-01 CU CU2021000023A patent/CU20210023A7/es unknown
- 2019-10-01 ES ES19782756T patent/ES2974208T3/es active Active
- 2019-10-01 SG SG11202102674RA patent/SG11202102674RA/en unknown
- 2019-10-01 MA MA053808A patent/MA53808A/fr unknown
- 2019-10-01 CA CA3114702A patent/CA3114702C/en active Active
- 2019-10-01 JP JP2021518191A patent/JP7048823B2/ja active Active
- 2019-10-01 GE GEAP201915599A patent/GEP20227442B/en unknown
- 2019-10-01 WO PCT/IB2019/058355 patent/WO2020070651A1/en not_active Ceased
- 2019-10-01 CN CN201980080149.6A patent/CN113166177B/zh active Active
- 2019-10-01 PE PE2021000415A patent/PE20211546A1/es unknown
- 2019-10-01 DK DK19782756.1T patent/DK3861001T3/da active
- 2019-10-01 IL IL282083A patent/IL282083B2/en unknown
- 2019-10-03 UY UY0001038400A patent/UY38400A/es not_active Application Discontinuation
- 2019-10-04 US US16/593,171 patent/US10946031B2/en active Active
- 2019-10-04 TW TW108135972A patent/TWI764052B/zh active
- 2019-10-04 PY PY201901983118A patent/PY1983118A/es unknown
-
2020
- 2020-10-28 US US17/082,102 patent/US11559538B2/en active Active
-
2021
- 2021-03-18 ZA ZA2021/01822A patent/ZA202101822B/en unknown
- 2021-03-18 NI NI202100020A patent/NI202100020A/es unknown
- 2021-03-29 CO CONC2021/0003928A patent/CO2021003928A2/es unknown
- 2021-03-31 DO DO2021000055A patent/DOP2021000055A/es unknown
- 2021-04-05 CL CL2021000843A patent/CL2021000843A1/es unknown
- 2021-04-05 PH PH12021550743A patent/PH12021550743A1/en unknown
- 2021-04-05 EC ECSENADI202123404A patent/ECSP21023404A/es unknown
-
2022
- 2022-12-15 US US18/066,468 patent/US20230148402A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21023404A (es) | Inhibidores de pde4 que contienen boro | |
| MX2020007383A (es) | Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47. | |
| ECSP24026455A (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
| MX2023001917A (es) | Inhibidores de la fosfatasa shp2 y metodos para su uso. | |
| NI201400121A (es) | Compuestos de indol e indazol que activan la ampk | |
| UY33245A (es) | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas | |
| JOP20180113B1 (ar) | مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية | |
| ECSP16067303A (es) | Heteroarilos y usos de estos | |
| NZ764644A (en) | Oxy-fluoropiperidine derivative as kinase inhibitor | |
| MX2020006708A (es) | Derivado de amino-fluoropiperidina como inhibidor de cinasa. | |
| BR112017006705A2 (pt) | inibidores de biossíntese de sulfato de heparan para o tratamento de doenças | |
| CO2021003391A2 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| ECSP13012600A (es) | CO-cristales y Sales de Inhibidores de CCR3 | |
| MA38884A1 (fr) | Composé de triazolopyridine, compositions et procédés d'utilisation associés | |
| MX2019008331A (es) | Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. | |
| CO2021001174A2 (es) | Inhibidores de ckd8/19 | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
| EA201591369A1 (ru) | Новые производные пиримидина в качестве ингибиторов фосфодиэстеразы 10 (pde-10) | |
| SA521430837B1 (ar) | مركبات مثبطة لمبادل الصوديوم-الهيدروجين 3 | |
| CL2020001089A1 (es) | Compuestos inhibidores de tirosina cinasa de bruton (btk). | |
| EA202190690A1 (ru) | Борсодержащие ингибиторы pde4 | |
| MA39204B1 (fr) | Derives hétéroaryles inhibiteurs de vps34 et/ou de p13 pour le traitement de troubles proliferatifs, inflammatoires ou cardiovasculaires | |
| MA44503B1 (fr) | Composés de pyrrolotriazine en tant qu'inhibiteurs de tam | |
| EA201891687A9 (ru) | Новые замещённые производные цианиндолина в качестве nik-ингибиторов | |
| MA35151B1 (fr) | Composés microarn et procédés pour la modulation de l'activité de mir-21 |